12 Month Price Forecast For MDNA
Distance to MDNA Price Forecasts
MDNA Price Momentum
๐ค Considering Medicenna (MDNA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 14, 2025 12:36 PM UTC
MDNA Analyst Ratings & Price Targets
MDNA has shown a year-to-date change of -85.7% and a 1-year change of -77.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MDNA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDNA Analyst Consensus
MDNA Price Target Range
Latest MDNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDNA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 6, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
Aug 14, 2023 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $3.00 |
Aug 10, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
Jul 31, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
Jun 28, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
Feb 8, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
Nov 8, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $2.50 |
Aug 16, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $4.00 |
Jun 23, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $5.00 |
Jun 23, 2022 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $10.00 |
Jun 1, 2021 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $7.00 |
Dec 18, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
Dec 17, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
Nov 25, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
Sep 10, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Medicenna Therapeutics Corp.
The following stocks are similar to Medicenna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medicenna Therapeutics Corp. (MDNA) Financial Data
Medicenna Therapeutics Corp. has a market capitalization of $10.93M with a P/E ratio of -1.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of -34.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Medicenna Therapeutics Corp. (MDNA) Company Overview
About Medicenna Therapeutics Corp.
Develops immunotherapies for cancer treatment.
Medicenna Therapeutics Corp. focuses on the development and commercialization of innovative immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its drug candidates, which are designed to enhance immune responses against cancer and autoimmune diseases, with multiple products advancing through various stages of clinical trials.
The company's lead product, MDNA55, targets recurrent glioblastoma, while MDNA11 and MDNA209 aim to activate immune cells and treat autoimmune conditions, respectively. Medicenna also offers its proprietary BiSKITs platform for creating customized Superkines, expanding its potential market opportunities. Headquartered in Toronto, Canada, the company is positioned within a growing sector focused on advanced cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Fahar Merchant Ph.D.
Country
Canada
IPO Year
2015
Website
www.medicenna.comMedicenna Therapeutics Corp. (MDNA) Latest News & Analysis
Medicenna Therapeutics will present findings from its Phase 2b trial of bizaxofusp at the Society for Neuro-Oncology Annual Meeting from November 15-19, 2023, in Vancouver.
Medicenna's upcoming presentation at a key oncology meeting highlights progress in its IL-4R targeted therapy, potentially influencing investor confidence and stock performance.
Medicenna's MDNA11 shows promising results in the ABILITY-1 study, with significant tumor reductions in pancreatic and melanoma patients. The treatment is well tolerated with no severe side effects.
Positive clinical results for MDNA11 in advanced solid tumors enhance Medicenna's growth potential, signaling strong therapeutic prospects and possibly increased market interest and investment.
Medicenna Therapeutics (NASDAQ: MDNA) stock is declining after receiving a delisting notice from Nasdaq's Listing Qualifications Department.
Medicenna Therapeutics' delisting notice raises concerns about its financial stability and compliance, potentially leading to decreased investor confidence and stock value.
The Company's listing on the Toronto Stock Exchange remains unaffected.
Stable listings signal confidence and continuity, reducing volatility risk and maintaining investor trust in the company's market presence.
Medicenna Therapeutics Corp. will present posters at the SITC Annual Meeting in San Diego from November 1-5, 2023, focusing on its Superkines immunotherapy developments.
Medicenna's participation at a prominent immunotherapy conference could attract investor interest, signal progress in their research, and potentially influence stock performance based on new data or partnerships.
New data from a Phase 1 trial will be presented at the SITC Annual Meeting on November 4, 2023, potentially impacting investor interest in related biotech firms.
Upcoming trial results could impact stock prices of companies involved in cancer therapies, influencing investor sentiment and potential market opportunities.
Frequently Asked Questions About MDNA Stock
What is Medicenna Therapeutics Corp.'s (MDNA) stock forecast for 2025?
Analyst forecasts for Medicenna Therapeutics Corp. (MDNA) are not currently available. The stock is trading at $0.16.
Is MDNA stock a good investment in 2025?
Analyst ratings for MDNA are not currently available. The stock is currently trading at $0.16. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MDNA stock?
Price predictions from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.
What is Medicenna Therapeutics Corp.'s business model?
Medicenna Therapeutics Corp. focuses on the development and commercialization of innovative immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its drug candidates, which are designed to enhance immune responses against cancer and autoimmune diseases, with multiple products advancing through various stages of clinical trials.
What is the highest forecasted price for MDNA Medicenna Therapeutics Corp.?
Price targets from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.
What is the lowest forecasted price for MDNA Medicenna Therapeutics Corp.?
Price targets from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.
What is the overall MDNA consensus from analysts for Medicenna Therapeutics Corp.?
Analyst ratings for MDNA are not currently available. The stock is trading at $0.16.
How accurate are MDNA stock price projections?
Stock price projections, including those for Medicenna Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.